Emmaus Life Sciences Secures Market Exclusivity for Endari in Saudi Arabia

Emmaus Life Sciences (OTCQB: EMMA) has secured a significant market advantage with the granting of market exclusivity for its sickle cell disease treatment, Endari® (L-glutamine oral powder), in the Kingdom of Saudi Arabia (KSA). The National Uniform Procurement Agency (NUPCO) has awarded Endari a one-year exclusivity period, with the potential for extension to three years upon marketing registration approval. This exclusivity applies across all KSA government institutions, including Ministry of Health hospitals, Military Hospitals, National Guard, Security Forces, and King Faisal Specialty Hospitals and Research Centers.

The KSA market represents a substantial opportunity for Emmaus, with an estimated 100,000 treatable sickle cell disease patients. The exclusivity period allows Emmaus to establish a strong foothold in the region and gain a competitive advantage over other potential competitors. Emmaus can now focus on building relationships with local healthcare providers, patient advocacy groups, and government institutions to increase awareness and access to Endari®.



Emmaus has already made progress in other Middle East and North Africa (MENA) markets. In 2022, the company received marketing authorization for Endari® in the United Arab Emirates (U.A.E.) and Qatar. Emmaus estimates that there are approximately 225,000 sickle cell disease patients in the MENA region who could potentially be treated with Endari®. This suggests that there are still numerous opportunities for Emmaus to target other markets in the region for similar exclusivity.



Some potential markets for Emmaus to consider include Bahrain, Kuwait, and Oman. Emmaus has already submitted a marketing authorization application for Endari® in Bahrain, and the drug is currently available on an early access basis. With a significant sickle cell disease patient population, Bahrain could be an attractive market for Emmaus to pursue. Similarly, Endari® is available on an early access basis in Kuwait, and Emmaus has not yet submitted a marketing authorization application in Kuwait, but the market represents another potential opportunity for the company to expand its presence in the MENA region.

In conclusion, the market exclusivity granted to Emmaus in the KSA is a significant development that strengthens the company's strategy for expanding its presence in the MENA region. By targeting other markets in the region, such as Bahrain, Kuwait, and Oman, Emmaus can continue to grow its business and improve the lives of sickle cell disease patients. The financial implications of this market exclusivity for Emmaus Life Sciences can be substantial, considering the size of the sickle cell disease patient population in the KSA and the potential for increased sales and revenue.